Ivacaftor improves insulin secretion in CF patients, suggesting a direct role of CFTR in β-cell function. The drug may slow down or prevent diabetes progression, particularly if initiated early. Larger and long-term studies are needed to confirm these effects and evaluate whether early CFTR correction could delay or prevent diabetes in CF patients. Here, INS is linked to diabetes mellitus.